Phase 2 N=23 NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
Lymphoblastic Lymphoma
Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=39 Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
Lymphoma, B-Cell
Primary: 1 Year Progression-free Survival Rate — 0.74 percentage of participants
Phase 2 N=57 A Study for Patients With Non-Hodgkin's Lymphomas
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Phase 2 N=14 Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma · Hepatosplenic T-cell Lymphoma
Primary: Overall Response (OR) Rate — 0.07 Proportion of participants
Phase 2 N=65 Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)
Lymphoma, Non-Hodgkin
Primary: Progression-Free Survival (PFS) — 73 percentage of participants
Phase 2 N=28 Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL
Lymphoma
Primary: Progression-free Survival at 1 Year — 38 percentage of participants
Phase 2 N=31 Antineoplaston Therapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
Low-Grade Lymphoma
Primary: Number of Participants With Objective Response — 1; 2; 14; 6 Participants
Phase 1 N=79 Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma
Lymphoma, B-Cell
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 29; 49; 11; 15 participants
Phase 2 N=11 Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma
High Risk Non-Hodgkin's Lymphoma
Primary: Assess the Efficacy of Combination Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma — 6 Participants
Phase 2 N=106 Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
AIDS-related Diffuse Large Cell Lymphoma · AIDS-related Immunoblastic Large Cell Lymphoma · AIDS-related Peripheral/Systemic Lymphoma
Primary: Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment — 0.69; 0.53 proportion
Phase 2 N=34 Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma
Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma · Hepatosplenic T-cell Lymphoma
Primary: Complete Response Rate of Cyclophosphamide, Etoposide, Vincristine and Prednisone (CEOP) and Pralatrexate (P) Treatment — 52 percentage of participants analyzed
Phase 2 N=100 Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: 2-year Progression-Free Survival (PFS) — 0.76; 0.42 probability
Phase 2 N=30 The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)
Non-Hodgkin Lymphoma · Hodgkin Disease
Primary: Summary of Adverse Events (AEs) — 9; 13; 7; 12 participants
Phase 2 N=72 Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Primary: Overall Response Rate (ORR) and Disease Control Rate (DCR) Per Investigator at 6 Months (FAS) — 11.5; 22.7; 25.0; 30.8 percentage of participants
Phase 2 N=191 A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma · Follicular Lymphoma
Primary: Part A, Phase I — 0; 1; 3; 0 Participants
Phase 2 N=17 Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Leukemia · Lymphoma
Primary: Survival at 1 Year After Transplantation — 10; 6 participants
Phase 2 N=46 S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
Lymphoma
Primary: Progression-free Survival — 89 percentage of participants
Phase 3 N=524 Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Large B Cell Lymphoma
Primary: Progression-Free Survival Rate at 2 and 5 Years — 78.9; 75.5; 68.0; 66.0 percentage of participants — p=0.6519
Phase 1 N=7 A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Primary: Number of Participants With Dose-limiting Toxicities (DLTs) — 0 Participants
Phase 2 N=30 Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Primary: Objective Response Rate — 18.8; 33.3; 30.0 Percentage of Patients
Phase 3 N=253 SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
Lymphoma
Primary: 2-year Overall Survival Rates — 71.1; 73.7 percentage of participants
Phase 3 N=503 Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Phase 2 N=17 LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
Phase 2 N=23 PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma
B-Cell Lymphoma
Primary: Clinical Response Rate — 1; 7; 0; 8 Participants
Phase 2 N=32 Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma
Contiguous Stage II Grade 1 Follicular Lymphoma · Contiguous Stage II Grade 2 Follicular Lymphoma · Contiguous Stage II Marginal Zone Lymphoma
Primary: Progression-free Survival — 92; 71; 83; 71 Kaplan-Meier estimated % of patients
Phase 2 N=50 Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)
Non-Hodgkins Lymphoma
Primary: Percentage of Participants With Response — 34.7 percentage of participants
Phase 2 N=67 Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial
Lymphoma
Primary: Number of Participants in Complete Remission 6 Months After Randomization — 14; 9 Participants
Phase 3 N=322 Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Primary: Event-free Survival (EFS) Per Blinded Independent Review Committee (BIRC) Assessment — 3.0; 3.0 months — p== 0.694
Phase 2 N=144 An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas
Non-Hodgkin's Disease
Primary: Safety Analysis - Number of Participants With Dose Limiting Toxicities (DLT) in the DLT Evaluation Phase — 0; 0; 0 Participants
Phase 2 N=51 Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Anaplastic Large Cell Lymphoma · Recurrent Adult Burkitt Lymphoma · Recurrent Adult Diffuse Large Cell Lymphoma
Primary: Objective Overall Response Rate — 14; 0 participants — p=0.022